NCT03922347

Brief Summary

This study is a community trial that aims to establish and evaluate an mHealth screening and promotional tool for improving eye health in Iran. Sampling frame is a region in Tehran province with around 1 million sub-urban and rural inhabitants. investigators have obtained the list of health centers and their underserved population from the health authorities. In this region, health services are delivered through rural health houses, urban health posts and overhead health centers (221 units in total). investigators choose 27 units using cluster random sampling method with a probability proportional to size strategy, then investigators randomly assign them into three arms (explained below). The interventions will be at community level with the community as the unit of randomization. Arm 1- Training of the Primary Health Care (PHC) workers + PHC workers will be empowered with the mHealth tool to monitor, screen and promote community members Arm 2- PHC system will be strengthened with health promotion and screening programmes (same content as the mHealth tool) and PHC workers will deliver eye health messages and screening tests by the conventional facilities. Arm 3: Control group: only observation and registering of routine care

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3,300

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Apr 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 15, 2017

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 15, 2018

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 10, 2019

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

April 13, 2019

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 19, 2019

Completed
Last Updated

April 23, 2019

Status Verified

April 1, 2019

Enrollment Period

1.1 years

First QC Date

April 13, 2019

Last Update Submit

April 20, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Eye care utilization: being visited/treated by an eye care professional

    Questionnaire based on closed questions

    6-12 months

Secondary Outcomes (4)

  • Visual acuity

    At baseline

  • fundus imaging

    At baseline

  • Based on Logarithm Minimum Angle of Resolution, LogMAR. Visual acuity will be presented in range (minimum to maximum). Higher value of visual acuity represents the worsened outcome.

    At baseline

  • fundus imaging by fundus photography (Visucam Pro NM; Carl Zeiss Meditec AG, Germany)

    At baseline

Study Arms (3)

routine care

NO INTERVENTION

Screening program including 2 consecutive tests

ACTIVE COMPARATOR
Diagnostic Test: Screening program including 2 consecutive tests

Screening program with mobile health

ACTIVE COMPARATOR
Diagnostic Test: Screening program with mobile health

Interventions

visual acuity test by Snellen chart, fundus imaging by fundus photography (Visucam Pro NM; Carl Zeiss Meditec AG, Germany)

Screening program including 2 consecutive tests

Peek Acuity and Peek Retina installed on smart phones (Samsung Galaxy S8)

Screening program with mobile health

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ophthalmic Research Center

Tehran, Iran

Location

MeSH Terms

Conditions

Vision Disorders

Condition Hierarchy (Ancestors)

Sensation DisordersNeurologic ManifestationsNervous System DiseasesEye DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of ophthalmic research center

Study Record Dates

First Submitted

April 13, 2019

First Posted

April 19, 2019

Study Start

April 15, 2017

Primary Completion

May 15, 2018

Study Completion

April 10, 2019

Last Updated

April 23, 2019

Record last verified: 2019-04

Locations